arrow
B

Benedetto Maurizio Celesia

university of catania
H指数:28
被引数:3,691

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Virologic, Lipid, Renal and Hepatic Laboratory Outcomes After Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Treatment-Experienced People with HIV: Real-World Evidence from the SHINe-SHIC Cohort

在治疗经验丰富的HIV感染者中,从其他方案转换为多拉韦林/拉米夫定/富马酸替诺福韦二吡呋酯后的病毒学、血脂、肾脏和肝脏实验室结局:来自SHINe-SHIC队列的真实世界证据

2026-09-180
OA
Distance from low-density lipoprotein cholesterol targets across cardiovascular risk strata in people living with HIV: A multicentre cohort study

HIV感染者中低密度脂蛋白胆固醇目标值的达标距离及其心血管风险分层:一项多中心队列研究

2026-07-010
OA
Cognitive and fine motor performance in people above 65 years of age with and without HIV

65岁以上人群的认知和精细运动表现:HIV感染者与非感染者的比较

2026-05-140
OAAI
The Role of Immune Dysregulation Markers in Cardiovascular Risk of People Living with HIV: Association Among Intima Media Changes, CD4/CD8 Ratio, and CD4+ Cell Count Nadir

免疫失调标志物在人类免疫缺陷病毒感染者心血管风险中的作用:内膜中层变化、CD4/CD8 比值与 CD4+ 细胞计数谷值之间的关联

Viruses
IF3.5
2026-03-180
OAAI
Efficacy and Safety of Cabotegravir–Rilpivirine in PLWH: A Real-World Study

卡博格韦–利匹韦林在PLWH中的疗效与安全性:一项真实世界研究

Viruses
IF3.5
2026-03-030
OAAI
Bimonthly Administered Long-Acting Cabotegravir and Rilpivirine Are Highly Effective and Well-Tolerated in People With Human Immunodeficiency Virus Above 65 Years

每两个月给药的长效卡博特韦和 rilpivirine 在 65 岁以上的人类免疫缺陷病毒感染者中具有高效性和良好的耐受性

2026-01-010
PRE
Correction: Health profiles of foreign-born elderly women with HIV in Italy

更正:意大利外裔老年女性HIV患者的健康档案

2025-11-070
OAAI
Health profiles of foreign-born elderly women with HIV in Italy

在意大利的HIV感染的外国出生老年女性的健康状况档案

2025-09-290
OAAI
Viro-Immunological Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide among Women Living with HIV: A 96-Week Post-Switch Analysis from the Real-Life SHiNe-SHiC Cohort
2024-10-111
OAAI
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry
2024-07-153
PRE
Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study
2024-04-153
OAAI
Pillars of long-term antiretroviral therapy success

长期抗逆转录病毒疗法成功的支柱

2023-10-013
OAAI
Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting

具有抗逆转录病毒治疗经验的HIV感染者的脂质和转氨酶,转换为基于Doravirine的方案与基于Rilpivirine的方案: 来自现实生活中的数据

2023-07-238
OAAI
Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens
2023-04-145
OAAI
Incident diabetes in course of antiretroviral therapy

在抗逆转录病毒治疗过程中发生糖尿病

AIDS
IF3.1
2023-03-145
PRE
Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study
2023-03-108
OAAI